The neuronal glycine transporter GLYT2 takes up glycine from the extracellular space by an electrogenic process where this neurotransmitter is co-transported with sodium and chloride ions. We report in this paper that tyrosine at position 289 of GLYT2a is crucial for ion coupling, glycine affinity and sodium selectivity, stressing the essential role played by this residue of transmembrane domain III in the mechanism of transport. Substitution to tryptophan (Y289W), phenylalanine (Y289F), or serine (Y289S), renders transporters unable to catalyze glycine uptake. Measurements of glycine evoked steady-state currents in transfected HEK-293 cells reveal EC 50 values for glycine 17-fold (Y289F) and 45-fold (Y289S) higher than that of the wild type transporter. Sodium dependence is severely altered in tyrosine 289 mutants, both at the level of apparent affinity and cooperativity, with the more dramatic change corresponding to the less conservative substitution (Y289S). Accordingly, sodium selectivity is gradually lost in Y289F and Y289S mutants, and chloride dependence of glycine evoked currents is markedly decreased in Y289F and Y289S mutants. In the absence of threedimensional information from these transporters, these results provide experimental evidence supporting the hypothesis of transmembrane domain III being part of a common permeation pathway for substrate and cotransported ions.Glycine is a major inhibitory neurotransmitter in the spinal cord and the brain stem of vertebrates, where it participates in a variety of motor and sensory functions. In addition, glycine positively modulates the action of glutamate, the main excitatory neurotransmitter in the brain, on postsynaptic NMDA 1 receptors. The re-uptake of glycine into presynaptic nerve terminals or the surrounding fine glial processes plays a major role in the maintenance of low synaptic levels of the transmitter (1-3). It is now well demonstrated that hypofunction of glutamatergic (NMDA receptor-mediated) neurotransmission is involved in symptoms of schizophrenia (4). It is also likely that a decrease in the glycinergic inputs is involved in pathologies of the muscle tone regulation (5). Therefore, compounds able to potentiate glycinergic neurotransmission may find applications in the treatment of psychiatric diseases and spasticity (6).Glycine transporters are members of the Na ϩ -and Cl Ϫ -dependent neurotransmitter transporter family (7-9), a group of integral glycoproteins (10, 11) that share a common structure with 12 transmembrane domains (12). Several neurotransmitter uptake systems, including those for glycine, present an unexpected molecular heterogeneity.By now, two glycine transporters, GLYT1 and GLYT2, have been cloned (13-17). GLYT1 presents three isoforms (GLYT1a, GLYT1b, and GLYT1c) that differ in their amino-terminal sequences and are generated both by alternative promoter usage and by alternative splicing (13,15,17,18). Recently, a second GLYT2 isoform (GLYT2b) has been isolated, cloned, and characterized in our laboratory (19). The GLYT...